Immutep Limited (IMMP) and Dr. Reddy's Laboratories Ltd. (RDY) on Monday said their subsidiaries have agreed to partner on the development and commercialisation of Eftilagimod Alfa (efti) in all markets outside North America, Europe, Japan, and Greater China.
Efti, Immutep's lead immunotherapy candidate, is currently being evaluated in a registrational Phase III trial as a first-line treatment for advanced or metastatic non-small cell lung cancer. It is also under investigation across several additional indications, including head and neck cancer, breast cancer, and soft tissue sarcoma.
Under the agreement, Immutep will receive a $20 million upfront payment from Dr. Reddy's and is eligible for up to $349.5 million in potential regulatory, development, and commercial milestone payments, along with double-digit royalties on future sales in the licensed markets.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.